Latest Hepatitis C/co-infection with HIV Stories

ABBOTT PARK Ill., April 4, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress(TM) 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain. Abstracts for the meeting were published online today. In the study known as "Co-Pilot," different doses of ABT-450/r,...

HUDDINGE, Sweden, April 4, 2012 /PRNewswire/ -- - Including an Oral Presentation of final analysis of the TMC435 phase IIb ASPIRE (C206) study that have been selected to be highlighted during the official EASL Press Office activities Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, today announces that four abstracts related to its once daily (QD), oral investigational hepatitis C drug TMC435, development in...

A study in this week's PLoS Medicine suggests that when people are first infected with HIV (primary HIV infection), temporary treatment with antiretroviral drugs (cART) for 24 weeks can delay the need to restart treatment during chronic HIV infection. These findings are important as currently, treatment for people with HIV is often deferred until the CD4 count falls below a certain level (350) or is based on clinical symptoms. In a study led by Marlous Grijsen from the Academic Medical...

HUDDINGE, Sweden, March 13, 2012 /PRNewswire/ -- - Study in previous non-responder Hepatitis C genotype-1 infected patients - Study in Hepatitis C genotype-4 infected patients MedivirAB (OMX: MVIR) a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has...

SAN DIEGO, Feb. 7, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that a presentation of the Aethlon Hemopurifier® to treat Hepatitis C virus (HCV) and other infectious disease conditions will occur at the upcoming 32(nd) Annual Dialysis Conference to be held on February 26-28 at the Henry B. Gonzalez Convention...

CAMBRIDGE, Mass., Feb. 3, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on IDX184 has been removed and that the Company's 12-week phase IIb study evaluating IDX184 in combination with pegylated interferon and...

SAN DIEGO, Feb. 1, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the administration of Hemopurifier® therapy during the first three days of standard of care peginterferon+ribavirin (PR) drug therapy has demonstrated both immediate and rapid virologic responses in genotype-1 infected HCV patients. An immediate...

Researchers targeted the type of hepatitis C most common in the United States, results reported in New England Journal of Medicine ANN ARBOR, Mich., Jan. 19, 2012 /PRNewswire-USNewswire/ -- A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist. The study, published Jan. 19 in the New England Journal of...

Researchers targeted the type of hepatitis C most common in the United States, results reported in New England Journal of Medicine A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist. The study, which will be published Jan. 19 in the New England Journal of Medicine, focused on hepatitis C genotype 1, which is...

CAMBRIDGE, Mass., Jan. 9, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection. IDX184, a pan-genotypic oral nucleotide polymerase inhibitor, has demonstrated a high barrier to...